Skip to search formSkip to main contentSkip to account menu

tosedostat

Known as: 2-(2-(hydroxy(hydroxycarbamoyl)methyl)-4-methylpentanoylamino)-2-phenylethanoic acid cyclopentyl ester, Aminopeptidase inhibitor CHR-2797, Cyclopentyl (2S)-2-{(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4- methylpentanamido}-2-phenylacetate 
A proprietary orally bioavailable inhibitor of the M1 family of aminopeptidases with potential antineoplastic activity. Aminopeptidase inhibitor CHR… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (1)

CHR-2797

Broader (2)

GlycineHydroxamic Acids
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Survival Benefit of Novel Drug Combinations Using Hypomethylating Agents for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Systemic Review
Background - Acute myeloid leukemia (AML) in elderly patients (>65 years) is associated with poor prognosis with median overall… 
2017
2017
A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
410Background: Recent advances in front-line therapy have improved survival in patients with advanced PDAC. A fluorouracil-based… 
2017
2017
Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy
2016
2016
A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic adenocarcinoma.
TPS471 Background: Metastatic pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Recent advances with fluorouracil… 
2011
2011
Cell Therapeutics Expands its Late-Stage Oncology Pipeline with Chroma Therapeutics’ Tosedostat
Cell Therapeutics (CTI) has licensed exclusive marketing and co-development rights in North, Central and South America to Chroma… 
2010
2010
The OPAL study: A phase II study to evaluate the efficacy, safety, and tolerability of tosedostat (CHR-2797) in elderly subjects with treatment refractory or relapsed acute myeloid leukemia.
TPS277 Background: Tosedostat (CHR-2797) is a novel oral aminopeptidase inhibitor. Aminopeptidases catalyze hydrolysis of… 
2009
2009
Inhibition of HDACs and Aminopeptidases Is Highly Synergistic in Myeloma Cells Resulting in Cell Death Via the Upregulation of BIRC3, a Key Mediator of NF-KappaB Signalling.
Abstract 607 Myeloma cells rely on a number of mechanisms to maintain their survival, including the silencing of genes that would… 
2009
2009
Cancer Therapy : Clinical A First-inMan Phase I and Pharmacokinetic Study on CHR-2797 ( Tosedostat ) , an Inhibitor of M 1 Aminopeptidases , in Patients with Advanced Solid Tumors
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary therapeutic activity… 
2009
2009
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)